Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 17/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30145157 | 1.00 | PDCD1 (0.55) | PDCD1CD274PRMT5WDR77MAPK8 | |
| SCHEMBL21565000 | 0.91 | PDCD1 (0.58) | PDCD1CD274 | |
| SCHEMBL30145362 | 0.88 | PDCD1 (0.53) | PDCD1CD274MAPK8GRAMD1A | |
| SCHEMBL20293195 | 0.88 | PDCD1 (0.53) | PDCD1CD274MAPK8GRAMD1A | |
| SCHEMBL30010862 | 0.87 | PDCD1 (0.46) | PDCD1CD274MAPK8GRAMD1A | |
| SCHEMBL20293591 | 0.87 | PDCD1 (0.54) | PDCD1CD274MAPK8 | |
| SCHEMBL29812811 | 0.87 | PDCD1 (0.54) | PDCD1CD274MAPK8 | |
| SCHEMBL22675301 | 0.85 | PDCD1 (0.59) | PDCD1CD274 | |
| SCHEMBL20294264 | 0.84 | PDCD1 (0.81) | PDCD1CD274 | |
| SCHEMBL20294297 | 0.84 | PDCD1 (0.66) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| EP-4520328-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118908978-A | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-112752756-B | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-03 | — | — | US | disclosed |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-11-14 | — | — | US | disclosed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | disclosed |
| EP-3558990-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119224-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119224-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885PRMT5 2076/4885 |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885PRMT5 2076/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | PDCD1 3/4885CD274 1/4885PRMT5 3517/4885 |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | IL2, IL4, NFATC1 | PDCD1 167/4885CD274 73/4885PRMT5 1059/4885 |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885PRMT5 2076/4885 |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885PRMT5 2076/4885 |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | PDCD1 3/4885CD274 1/4885PRMT5 3517/4885 |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885PRMT5 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.